CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Home Biopharma News Biopharma stages a strong recovery over the first half even as M&A deals disappoint
News
4 Aug 2017

Biopharma stages a strong recovery over the first half even as M&A deals disappoint

EP Vantage releases half-year reviews of pharma & biotech and medtech performance.

EP Vantage has released its 2017 half-year reports on pharma & biotech and medtech sector performance. Report authors Elizabeth Cairns and Jon Gardner provide their expert viewpoints, powered by Evaluate data and consensus forecasts. Key findings include

Pharma & Biotech:

  • Nasdaq Biotechnology Index hit an 18-month high, and healthcare indices in general outperformed wider markets over the first half
  • Initial public offerings of development-stage companies exceeded $1bn in the second quarter, making it the strongest quarter in nearly 2 years
  • The first half of 2017 generated the lowest number of M&A deals and total transaction value since 2013
  • Venture capital investment looks to be on track to at least match 2016’s total
  • 2017 new drug approvals should recover to close to the five-year average, putting to rest any fears of a regulatory or innovation slowdown
  • Approaching regulatory decisions on the first CAR-T therapies will help set the tone for the remainder of the year.

    • Medtech:

  • Total venture funding raised in the first quarter was over $2.5bn, more than twice the quarterly average over the past seven years, but the second quarter saw the fewest deals since the second quarter of 2006
  • The first half of this year saw the three biggest ever VC rounds in medtech, Grail, Verily and Guardant Health raising more than $2bn between them
  • The mega-merger is back in vogue with nine out of the top 10 deals in the first half worth $1bn or more, versus only five in the first half of 2016
  • 2017 could see nearly $98bn spent on medtech M&A – double last year’s total – but with only around 150 transactions versus 234 in 2016
  • 2017 on course for the highest-ever number of approvals: 52 PMAs and HDEs combined and 34 de novo clearances.

    • Related tags
    Biopharma Market

    Related News

    • Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

      News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

      A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
      2 Jul 2026
    • Protecting life-saving therapies: CPHI Online Podcast Series

      News Protecting life-saving therapies: CPHI Online Podcast Series

      The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

      17 Jun 2026
    • 2026 Outsourcing Outlook Update - pharma at a crossroads

      News 2026 Outsourcing Outlook Update - pharma at a crossroads

      The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
      17 Jun 2026
    • Roche maintains German investment commitment whilst rivals scale back

      News Roche maintains German investment commitment whilst rivals scale back

      Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

      9 Jun 2026
    • Women in Pharma: The History of CPHI Women in Japan

      News Women in Pharma: The History of CPHI Women in Japan

      Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
      4 Jun 2026
    • EU drafts deal to end essential medicines shortage

      News EU drafts deal to end essential medicines shortage

      European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

      12 May 2026
    • Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

      News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

      The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
      30 Apr 2026
    • The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

      News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

      CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.
      29 Apr 2026